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Circulatory Support
The Problem of the UninsuredWe read with interest the recent report by Stretch
et al. (1) regarding the increase in the use of short-
term mechanical circulatory support (MCS) in the
United States. The investigators demonstrated that
the increased use of MCS has occurred together with
improved in-hospital survival and decreased hospital
costs. Both aspects will need to demonstrate favor-
able trends for MCS to continue to gain widespread
acceptance for the treatment of cardiogenic shock.
The ﬁnancial implication of short-term MCS is the
topic we would like to discuss further.
An important question is whether health insurance
is a necessary prerequisite for MCS options. Accord-
ing to the investigators, 8.8% of MCS patients
between 2004 and 2007 and 6.7% between 2008 and
2011 were characterized as having “self-pay, no
charge, or other” as the primary payer. It is certainly
likely that the majority of these patients were unin-
sured. Furthermore, <10% of patients had Medicaid
as their primary insurance. There are no deﬁnitive
data on whether insurance status, or lack thereof, is a
determining factor in patients’ receiving appropriate
MCS therapy. Insurance status has been shown to
contribute to whether patients receive appropriate
medical therapy or percutaneous coronary interven-
tion for coronary artery disease and ST-segment
elevation myocardial infraction (2,3). Given the
much greater expense for MCS, it stands to reason
that ﬁnancial implications do have some role indetermining whether MCS is offered for patients in
cardiogenic shock. Although the investigators re-
ported that uninsured and Medicaid patients received
MCS therapy, it is unknown whether the percent of
patients in these categories is representative of the
entire cardiogenic shock population. Are uninsured
patients who require MCS being referred to and
accepted at centers that can perform this therapy?
The policy of individual MCS programs regarding
the uninsured is unknown. A recent survey of heart
transplantation programs revealed that 84% of pro-
grams required health insurance to actively list a
patient for transplantation (4). Whether the same is
true to consider short- or long-term MCS options is
unknown, but possibly very similar.
The decision to initiate short-term MCS may be just
one step in a pathway leading to long-term MCS and
possibly heart transplantation. The investigators
reported that 25% of patients who underwent short-
term MCS for heart failure indications eventually
underwent placement of permanent long-term de-
vices. Once patients have been stabilized with short-
term MCS devices, it can be difﬁcult to withhold
further treatment. Given the potential ﬁnancial im-
plications involved, it is not surprising that insurance
considerations will factor in the decision-making
process for hospitals to determine who is a candi-
date for short-term MCS. It remains to be seen if
the Patient Protection and Affordable Care Act will
change this dynamic by lowering the overall number
of uninsured patients. However, uninsured patients
in cardiogenic shock do not have time to wait for in-
surance to be obtained before deﬁnitive therapy is
needed. We recently published data showing that at
our institution, uninsured patients could undergo
placement of permanent MCS devices with successful
outcomes and subsequent attainment of health
insurance (5). Several of our patients were on short-
term MCS devices initially. Nonetheless, there is no
easy solution to the problem of uninsured patients in
cardiogenic shock. The ethics of withholding MCS to
uninsured patients in cardiogenic shock must be
vigorously debated in the United States, particularly
as MCS becomes more widespread and outcomes
continue to improve. A frank discussion of the
ﬁnancial implications both for patients and for the
health care system needs to be undertaken.*Navin Rajagopalan, MD
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Proceed With CautionIn a study recently published in the Journal, Dr.
Stretch and colleagues (1) described increasing utili-
zation of short-term mechanical circulatory support
(MCS) in the United States. The investigators found a
dramatic increase in the use of short-term MCS over
the past decade. The NIS (Nationwide Inpatient
Sample), used in this study, is an excellent resource
to study temporal trends on a large scale and is easily
available to researchers. The NIS, however, has limi-
tations that affect the interpretation of this study.
Hospitals are included to approximate a 20% sample
of all hospitals in the United States (2). The weighting
strategy used to create national estimates relies on
the assumption that similar hospitals have similar
experiences (3). This assumption is probably true
for common diagnostic codes, such as pneumonia
and urinary tract infection, but may not be true
for rarer events, such as short-term MCS. In other
words, all rural, large, government, nonteaching
hospitals in the Northeast (1 of 60 hospital strata in
the NIS) will not necessarily adopt MCS at similar
rates. The national estimates, therefore, are prone to
inaccuracy.
The cost methodology used in the NIS is on the basis
of schemas based on primary International Classiﬁca-
tion of Diseases, Ninth Revision, or diagnosticallyrelated groups schemas developed by the Agency
for Healthcare Research and Quality (4). The method-
ology does not directly account for length of stay and
therefore does not account for outlier payments. MCS
patients, however, may be more likely to have long,
complicated hospitalizations and qualify for outlier
payments. The investigators report “other” as the
indication for hospitalization in 20% to 25% of
encounters; the strategy used to calculate costs for this
signiﬁcant group of patients is unclear.
Anecdotal experience suggests that the ﬁndings
of this investigation are true: MCS use is probably
increasing. Still, investigators must ensure rigorous
methods to avoid inaccurate trend assessment.
Research using large datasets, such as the NIS, is
important in understanding health care delivery
trends on a broad scale. This type of research will
become more prevalent and important as adminis-
trative data become more readily available. There-
fore, an increased focus on methods is warranted.*Rashmee U. Shah, MD, MS
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